



# Psychedelic Inspired Medicines

January 2022

NASDAQ  
**MNMD**

NEO  
**MMED**

DE  
**MMQ**



# Disclaimer

This presentation (the "Presentation") has been prepared by Mind Medicine (MindMed) Inc. ("MindMed" or the "Company") solely for informational purposes. None of MindMed, its affiliates or any of their respective employees, directors, officers, contractors, advisors, members, successors, representatives or agents makes any representation or warranty as to the accuracy or completeness of any information contained in this Presentation and shall have no liability for any representations (expressed or implied) contained in, or for any omissions from, this Presentation. This presentation shall not constitute an offer, nor a solicitation of an offer, of the sale or purchase of securities. This Presentation does not constitute an offering of securities of MindMed and under no circumstances is it to be construed as a prospectus or advertisement or public offering of securities.

## Market and Industry Data

This Presentation includes market and industry data that has been obtained from third party sources, including industry publications. MindMed believes that the industry data is accurate and that the estimates and assumptions are reasonable, but there is no assurance as to the accuracy or completeness of this data. Third party sources generally state that the information contained therein has been obtained from sources believed to be reliable, but there is no assurance as to the accuracy or completeness of included information. Although the data is believed to be reliable, MindMed has not independently verified any of the data from third party sources referred to in this Presentation or ascertained the underlying economic assumptions relied upon by such sources. References in this Presentation to research reports or to articles and publications should be not construed as depicting the complete findings of the entire referenced report or article. MindMed does not make any representation as to the accuracy of such information.

## Cautionary Note on Forward-Looking Information

This Presentation contains "forward-looking statements" and "forward-looking information" within the meaning of applicable securities laws (collectively, "forward-looking information") with respect to MindMed and its subsidiaries. Statements in this Presentation that are forward-looking information are based on currently available competitive, financial, and economic data and operating plans as of the date of this Presentation but are subject to various risks and uncertainties concerning the specific factors disclosed herein. Often, but not always, forward-looking information can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", "will", "projects", or "believes" or variations (including negative variations) of such words and phrases, or statements that certain actions, events, results or conditions "may", "could", "would", "might" or "will" be taken, occur or be achieved. Except for statements of historical fact, information contained herein constitutes forward-looking information, including, but not limited to: statements pertaining to the development and commercialization of any medicine or treatment, or the efficacy of either of the foregoing, the likelihood of success of any clinical trials or of obtaining FDA or other regulatory approvals, the likelihood of obtaining patents or the efficacy of such patents once granted, and the potential for the markets that MindMed is anticipating to access.

Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management at the date the statements are made including among other things assumptions about: MindMed's ability to raise capital to complete its plans and fund its studies, the medical and commercial viability of the contemplated medicines and treatments being developed, and the ability of MindMed to raise additional capital in the future as MindMed continues to develop its products. While MindMed considers these assumptions to be reasonable, the assumptions are inherently subject to significant business, social, economic, political, regulatory, competitive and other risks and uncertainties, contingencies and other factors that could cause actual performance, achievements, actions, events, results or conditions to be materially different from those projected in the forward-looking information. These include the Company's history of negative cash flows; limited operating history; incurrence of future losses; availability of additional capital; lack of revenue; compliance with laws and regulations; difficulty associated with research and development; risks associated with clinical trials or studies; heightened regulatory scrutiny; early stage product development; clinical trial risks; regulatory approval processes; novelty of the psychedelic inspired medicines industry; as well as those risk factors discussed or referred to under the headings "Risk Factors" in the Company's final base shelf prospectus dated April 9, 2021 filed with the securities regulatory authorities in each of the provinces and territories of Canada and the Company's annual information form for the year ended December 31, 2020 filed with the securities regulatory authorities in all provinces and territories of Canada and available under the Company's profile on SEDAR at [www.sedar.com](http://www.sedar.com) and as described in the Company's U.S. registration statement on Form F-10 declared effective by the United States Securities and Exchange Commission (the "SEC") on April 12, 2021 and filed with the SEC on EDGAR at [www.sec.gov](http://www.sec.gov). Many assumptions are based on factors and events that are not within the control of MindMed and there is no assurance they will prove to be correct.

The United States federal government regulates drugs through the Controlled Substances Act. The Company works with a non-hallucinogenic synthetic derivative of the psychedelic substance ibogaine, known as "18-MC", which is a synthetic organic molecule designed around a common coronaridine chemical backbone. 18-MC is not a Schedule I substance in the United States and the Company does not foresee it becoming a Schedule I substance due to its non-hallucinogenic properties. While the Company is focused on programs using psychedelic inspired compounds and classic psychedelics, the Company does not have any direct or indirect involvement with the illegal selling, production or distribution of any substances in the jurisdictions in which it operates. The Company is a neuro-pharmaceutical drug development company and does not deal with psychedelic substances except within laboratory and clinical trial settings conducted within approved regulatory frameworks. The Company's products will not be commercialized prior to applicable regulatory approval, which will only be granted if clinical evidence of safety and efficacy for the intended uses is successfully developed.

Although MindMed has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking information, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: MindMed not being able to obtain the necessary FDA and other approvals, inconclusive or negative results from clinical trials, MindMed electing to not proceed with any of the medicines or treatments discussed herein, and MindMed not being able to build production capacity should its trials be successful. To the extent any forward-looking information contains forecasts or financial outlooks, such information is being provided solely to enable a reader to assess MindMed's financial condition and its operational history and experience in the pharmaceutical industry. Readers are cautioned that this information may be not appropriate for any other purpose, including investment decisions. Such information, as with forward-looking information generally, is, without limitation, based on the assumptions and subject to the risks and other cautionary statements set out above. The actual results achieved will vary from the forecast or financial outlook results and the variations may be material. No representation or warranty of any kind is or can be made with respect to the accuracy or completeness of, and no representation or warranty should be inferred from, our projections or the assumptions underlying them.

There can be no assurance that such information will prove to be accurate or that management's expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in this forward-looking information may differ materially from actual results or events. Because of the risks, uncertainties and assumptions contained herein, readers should not read forward-looking information as guarantees of future performance or results. Nothing in this presentation is, or should be relied upon as, a promise or representation as to the future. All amounts are in USD unless otherwise noted. Accordingly, readers should not place undue reliance on forward-looking information. The forward-looking information in this Presentation is made as of the date of this Presentation. MindMed disclaims any intention or obligation to update or revise such information, except as required by applicable law, and MindMed does not assume any liability for disclosure relating to any other company mentioned herein. Investors are cautioned not to unduly rely on this forward-looking information and are encouraged to read MindMed's continuous disclosure documents, including its current annual information form, as well as its audited annual consolidated financial statements which are available on SEDAR at [www.sedar.com](http://www.sedar.com) and on EDGAR at [www.sec.gov/edgar](http://www.sec.gov/edgar).

MindMed's securities have not been approved or disapproved by the SEC or by any state, provincial or other securities regulatory authority, nor has the SEC or any state, provincial or other securities regulatory authority passed on the accuracy or adequacy of this Presentation. Any representation to the contrary is a criminal offense.



# Investment Highlights

Robust, long-term strategy with near-term value drivers

## MindMed Differentiator

Advancing novel drug class to transform mental health treatment

Leveraging therapeutic potential of LSD with first-in-class strategy

Building diverse, robust, and long-term development pipeline

Multiple near-term value-driving catalysts

Accelerating value through collaborations

## Investment Highlights

- Leveraging rigorous drug development principles and enabling digital therapeutics
  - Approach supported by long history of well-tolerated use in clinical studies
  - Tech enables market access and scale
- Diversified strategy across development franchise with multiple ongoing and planned clinical studies
  - Opportunity for accelerated development
- Diverse pipeline of NCEs and optimized molecules derived from classic psychedelics
  - Initial focus on psychiatry, addiction and neurology with opportunity to explore follow-on indications
  - 8 ongoing/planned Phase 2 studies & 4 ongoing/planned Phase 1 studies
- (Early 2022) Initiate Phase 2b trial of LSD for Generalized Anxiety Disorder (GAD)
  - (Early 2022) Release Top-line Results from Phase 1 trial of 18-MC for opioid withdrawal
  - (Early 2022) Initiate Phase 2a trial of 18-MC for opioid withdrawal
- Collaborations with leading research and academic institutions further validate approach
  - Collaborations and data acquisitions enable rapid path to development with significantly less risk

SCHE: attention deficit hyperactivity disorder; PTSD: post-traumatic stress disorder



# MindMed is a Mental Health Company

Therapeutic area selection to address massive unmet needs

8

## Targeting Major Psychiatric Disorders

**51.5M** US adults suffering from mental illness <sup>1</sup>

## Increasing Burden over Time

**21%** One year prevalence of anxiety disorders in US <sup>2</sup>

## Major Driver of Overall Healthcare Costs


**\$225B** Annual cost of mental health in US <sup>15</sup>

## Current Treatments are Inadequate

**88%**  
of OUD patients relapse with  
buprenorphine discontinuation <sup>3</sup>

**59%**  
of GAD patients with  
residual symptoms <sup>4</sup>






**13%**  
of US Population with  
uncontrolled pain <sup>5</sup>



# Psychedelic-Inspired Medicine Opportunity

Illustrative purposes only

Multiple Generations of Potential Drug Candidates derived from Classic Psychedelics

	CONCEPT	MINDMED APPROACH			
CLASSIC PSYCHEDELICS	<ul style="list-style-type: none"> <li>Evidence of potential for positive clinical benefit</li> <li>Extensive prior human exposure</li> <li>Well-characterized pharmacology</li> <li>Potential to accelerate development program</li> </ul>	 <p>LSD</p>	 <p>MDMA</p>	 <p>PSILOCYBIN</p>	 <p>DMT</p>
2ND GENERATION / OPTIMIZED	<ul style="list-style-type: none"> <li>Pharmacologically optimized molecules and dosage forms</li> <li>Modifications to overcome potential safety liabilities</li> <li>Intellectual property generation</li> </ul>	Prodrugs and analogues	Novel dosage forms	Novel treatment models	Novel administration methods
3RD GENERATION / NCES	<ul style="list-style-type: none"> <li>Structural analogues to classic psychedelics</li> <li>Require full development program</li> <li>Strongest available intellectual property</li> </ul>	 <p>18-MC</p>	Novel tryptamines	Novel phenethylamines	Non-hallucinogenic analogues



# Advancing the Field with Strong IP & Strategic Competitive Moats

Protecting Innovation and Market Potential

## Our Patent Positions are Extensive and Diverse

**45+** patent applications filed

**45+** molecules covered

**30+** NCEs covered

**10+** Patent applications covering LSD

**3+** patent applications covering 18-MC









## Strategic Approach to Maximize Market Protection

- Composition of matter
- NCEs/psychedelic analogues
- Unexplored indications
- Optimized formulations with unique PK
- Proprietary methods of manufacturing
- Combination therapies
- AI and ML algorithms
- Innovative dosing protocols
- Physiochemical attributes



# Our Robust and Diverse Development Pipeline

Pipeline Diversification Offers Access To Full Potential Of Psychedelic Inspired Medicines

PRE-CLINICAL	PHASE 1	PHASE 2A	PHASE 2B	PHASE 3	COMMERCIAL LAUNCH
<p><b>Undisclosed</b> Substance use disorder</p> <p>Formulation optimization of psychedelics in brain-targeted liposomes</p> 	<p><b>18-MC</b> Substance use disorders</p> <p>Completed — SAD/MAD Safety and PK</p>	<p><b>18-MC</b> Opioid Withdrawal*</p> <p>Planned Early 2022 – 2-week, randomized, double-blind, placebo-controlled</p>	<p><b>LSD</b> Generalized Anxiety Disorder*</p> <p>Planned Early 2022 — 12-week, randomized, controlled, parallel-group, single administration, dose optimization</p>		
<p><b>Undisclosed</b> Preclinical</p> <p>Generation of novel psychedelic-related compounds for preclinical screening</p> 	<p><b>Mescaline</b> Phase 1 IIT</p> <p>Ongoing — Safety &amp; PK</p> 	<p><b>LSD</b> Adult ADHD</p> <p>Ongoing — 6-week, randomized, double-blind, placebo-controlled, parallel-group, twice weekly administration</p>			
<p><b>R(-)-MDMA</b> Social functioning / ASD</p> <p>Ongoing — Safety &amp; PK</p>	<p><b>DMT</b> Phase 1 IIT</p> <p>Ongoing — Safety &amp; PK</p> 	<p><b>LSD</b> IIT - Anxiety disorders</p> <p>Ongoing — Random-order, double-blind, placebo-controlled, cross-over</p> 			
	<p><b>LSD + Ketanserin</b> Phase 1 IIT</p> <p>Ongoing — Safety &amp; PK</p> 	<p><b>LSD</b> IIT - Major Depressive Disorder</p> <p>Ongoing — Randomised, double-blind, active-placebo-controlled</p> 			
		<p><b>LSD</b> Acute Pain</p> <p>Planned 2022 — Undisclosed design</p>			
		<p><b>LSD</b> Chronic Pain</p> <p>Planned 2022 — Undisclosed design</p>			
		<p><b>LSD</b> IIT - Cluster Headache</p> <p>Ongoing — randomized, double-blind, placebo-controlled, two-phase cross-over</p> 			

- PSYCHIATRY
- ADDICTION
- PAIN
- NEUROLOGY

# Near-Term and Intermediate Value Drivers

DRUG CANDIDATE	INDICATION	COMPLETED LATE 2021	2022	MILESTONE
<b>PSYCHIATRY FRANCHISE</b>				
LSD — <i>Project Lucy</i>	Generalized Anxiety Disorder		●	Open IND & Initiate Phase 2b study
	Anxiety disorders 		●	Complete IIT in anxiety disorders
LSD — <i>Project Flow</i>	Adult ADHD	●		Initiated Phase 2a proof-of-concept study
R(-)-MDMA	Social functioning / ASD		●	Initiate Phase 1 IIT
<b>ADDICTION FRANCHISE</b>				
18-MC — <i>Project Layla</i>	Opioid Use Disorder		●	Top-line Results from Phase 1 SAD/MAD study
			●	Initiate Phase 2a proof-of-concept study (Opioid Withdrawal)
<b>PAIN FRANCHISE</b>				
LSD — <i>Project Angie</i>	Acute Pain indication		●	Initiate Phase 2 clinical program
	Chronic Pain indication		●	Initiate Phase 1/2 clinical program
<b>NEUROLOGY FRANCHISE</b>				
LSD	Cluster Headache 		●	Complete IIT in cluster headache
<b>PRECLINICAL/PHASE 1</b>				
MM-823 			●	Formulation development and preclinical proof-of-concept
Mescaline*		●		Initiate Phase 1 IIT (ongoing)
DMT			●	Complete Phase 1 IIT
LSD + Ketanserin			●	Complete Phase 1 IIT






# Science & Background

The Case for Psychedelic-Inspired Therapies

# Psychedelic Inspired Medicines: A New Treatment Paradigm

A Strong Case for Psychedelic Research

LSD activates serotonin 5-HT<sub>2A</sub> receptors in brain regions that are dysregulated/leads to increased neuron excitability and may help modulate behavior



# LSD | Extensive Early Phase Characterization

Strong Historical Third Party Clinical Research Presents Opportunity for Accelerated Development

**1000+** patients treated in clinical trials


**29** published clinical studies of LSD

**12** published clinical studies since 2008

Preliminary evidence supporting utility in:

- Anxiety
- Depression
- Alcohol use disorder
- Pain

## Characteristics of LSD in Human Dosing



Source: [11]



# LSD | Stands Out Among the Psychedelic Drug Class Opportunities

Substantial Body of Evidence Supports Efficient Development

## LSD: Overlooked & Undervalued

- Single administration with rapid and sustained action
- Robust clinical response in a wide range of conditions
- Part of psychedelic drug class with strong efficacy in preliminary studies
- No required bioactivation for activity
- Highly potent with microgram therapeutic range





Fig. 1. Whole-brain cerebral blood flow maps for the placebo and LSD conditions, plus the difference map (cluster-corrected,  $P < 0.05$ ;  $n = 15$ ).


Source: [12]

# LSD | Emerging Evidence in Pain & Somatic Disorders

Applications Beyond Psychiatry



## Low Dose LSD Increases Pain Tolerance and Decreases Perceived Pain



Source: [14]




**Kim Kuypers PhD**

Associate Professor, Maastricht University

Leading researcher for repeat, sub-experiential LSD dosing

# LSD Clinical Development Program

Diversified Strategy Across Development Franchises






# Expanding Pipeline

# 18-MC | Psychedelic-Inspired NCE: 18-MC

Non-hallucinogenic, non-cardiotoxic congener of ibogaine


## 18-MC Targets Substance Abuse Disorders via Different Mechanisms than Existing Therapies




# 18-MC | Psychedelic-Inspired NCE

Extensive pre-clinical data supports clinical development strategy

## 18-MC Reduces Morphine and Cocaine Self-Administration in Animal Models of Substance Use Disorder



**18-MC**  
(mg/kg i.p.)



**18-MC**  
(mg/kg i.p.)



# R(-)-MDMA Program | Social Functioning in Autism Spectrum Disorder (ASD)

Significant unmet need for novel therapies to support individuals with ASD

## Early Data Suggests Potentially Promising Results:


- In a pilot clinical trial, participants with ASD showed strong and statistically significant improvements in social anxiety and functioning from episodic treatment with MDMA

**\$461B**

economic cost of ASD in the US predicted by 2025<sup>17</sup>

**12%**

of the US general population experience Social Anxiety Disorder at some point in life<sup>18</sup>



Change over time in LSAS total scores (MDMA n=8 at baseline, n=7 at all other time points; placebo n=4). The primary endpoint occurred 1 month after the second experimental session. The 6-month follow-up visit was 6 months after the primary endpoint. The MDMA group had a greater mean change from baseline than the placebo group at the primary endpoint (P=0.037) and at the 6-month follow-up (P=0.036). The line at LSAS score of 60 represents inclusion criteria minimum score.

Source: [16]

# Develop & Discover

# R&D Pipeline

Robust pipeline driven by collaborative arrangements



- Exclusive rights to completed and ongoing clinical study data
- Execution of Phase 1/2 studies on known and novel psychedelics
- Intended to enable efficient de-risking of new assets



- Portfolio of psychedelic-inspired NCEs
- Screening and lead optimization program ongoing
- Generates multiple patent filings



- Exclusive collaborative R&D agreement covering psychedelics
- Application of liposome technology to optimize delivery



# Collaborative Approach for Accelerating Value

Collaborations & Data Acquisition enable Rapid Path to Development With Significantly Less Risk

## Exclusive UHB License Agreement



**Matthias Liechi, MD, PhD**

*Professor & Head of Liechi Lab*



- More than ten years of clinical research on LSD
- Dozens of completed and ongoing psychedelic trials
- Exclusive rights to clinical data on LSD, psilocybin, MDMA, mescaline and DMT

## 18-MC Advanced by \$6.5 million NIDA Grant

- \$6.5 million NIDA grant in 2013
- Animal efficacy data across multiple substance use targets
- Extensive preclinical safety characterization



National Institute  
on Drug Abuse

## Data Rights Acquired from UHB

### Completed Phase 1

- ✓ LSD PK
- ✓ LSD fMRI
- ✓ LSD LAM
- ✓ LSD LDR
- ✓ SERT-Psilocybin
- ✓ MDMA-reboxetine interaction
- ✓ MDMA-duloxetine interaction
- ✓ MDMA-clonidine interaction
- ✓ MDMA-carvedilol interaction
- ✓ MDMA-doxazosin interaction
- ✓ MDMA-methylphenidate interaction
- ✓ MDMA-methylphenidate comparison
- ✓ MDMA-bupropion interaction
- ✓ MDMA-fear extinction
- ✓ MDMA-fMRI

### Ongoing Phase 1

- LSD MDMA
- LSD Ketanserin
- LSD Psilocybin and Mescaline
- DMT Regimen
- Mescaline dose response
- LSD Psilocybin

### Ongoing Phase 2

- LSD for Anxiety Disorders
- LSD for Cluster Headaches
- LSD for Depression

### Planned Phase 1

- LSD Bioequivalence
- MDMA-related compounds

# Deploy

Our Division To Enable Scalability & Accessibility of Our Drug Programs






# Digital Medicine: Multiple Components of the MindMed Platform

Scalable Delivery Platform to Enable Adoption Leveraging the Current Ecosystem


## Early Engagement & Education

- Patient education, engagement, preparation and assistance
- Deep digital diagnosis allows greater granularity to complement DSM diagnoses
- Support for treatment selection: modality dose, and timing




## Treatment Session

- In-session monitoring for safety, efficacy, and additional interventions
- Clinician decision support for drug and non-drug therapeutic sessions
- Predictive models linking interventions and treatment outcomes



## Longitudinal Patient Engagement

- Real world monitoring of trends for relapse prediction and re-treatment decisions
- Engagement in health maintenance behaviors
- AI models to inform psychotherapeutic intervention





# Commercial Principles for Scalability & Accessibility

Scalable Delivery Platform to Enable Leveraging of Current Ecosystem



## Digital Medicine

- Use digital medicine technology to promote outcomes and engagement at all phases of the development, deployment, and clinical lifecycle
- Build proprietary applications to increase patient engagement, enhance provider experience, and protect market share

## Building The Psychiatric Training Infrastructure

- Donating \$5 million over a 5-year period
- Establish the gold standard of training programs to educate healthcare providers and psychedelic researchers

## Innovative Medical Approaches

- Driving adoption of our drugs through enhancement of the existing psychiatric and psychotherapeutic infrastructure
- LSD neutralizer technology
- Value-based reimbursement models

# Psychedelics Driving Progressive Care and Payment Models


Complementary Digital Medicine Approach for Improved Mental Health Outcomes

Digital Measurement enables value-based clinical models

Driving engagement through friction reducing patient technologies

Drug pricing and reimbursement driven by measured health economics & outcomes research value

High value market for providers enabled by novel reimbursement mechanisms






# Digital Measures, Diagnostics & Therapeutics to Enable Commercial Viability

Building Toward Novel Care and Reimbursement Models

- 1 Build measurement, diagnostic and therapeutic models using real world data
- 2 Validate measures, diagnostics, and interventions through clinical studies run on internal app channels
- 3 Next-generation applications support full patient and provider journeys including treatments sessions and intersession monitoring
- 4 Embedded measures, diagnostics, and therapeutics to enable closed-loop value-based care and evidence for commercialization with payers








# Digital Platform Pipeline Progression Mirrors Drug Pipeline

Across Product Categories, Progression is Enabled by Technical Development and Clinical Research



TECHNOLOGY CANDIDATE	DISCOVERY & REAL-WORLD DATA	MINIMUM VIABLE PRODUCT & CLINICAL DATA COLLECTION	STUDY USE, ALGORITHM DEVELOPMENT & PRODUCT ENHANCEMENT	VALIDATION & FDA CLEARANCE	COMMERCIAL LAUNCH
<p><b>Anxiety &amp; Affective Disorders</b> Intrasection SaMD Component #2</p> <p>In development — Concept development</p>	<p><b>Anxiety &amp; Affective Disorders</b> Intrasection Monitoring Platform</p> <p>In development — Internal discovery and real world data analysis</p>	<p><b>Anxiety Disorders</b> Intrasection Monitoring Platform</p> <p>Planned Early 2022 — Large decentralized observational study</p>	<p><b>Agitation Detection &amp; Prediction</b> Transdiagnostic</p> <p>Ongoing — Multiple Study Environments </p>		
<p><b>Anxiety &amp; Affective Disorders</b> Intrasection SaMD Component #3</p> <p>In development — Concept development</p>	<p><b>Anxiety &amp; Affective Disorders</b> Intrasection SaMD Component #1</p> <p>In development — Internal discovery real world data analysis</p>	<p><b>Substance Use Disorders</b> Substance Use Detection</p> <p>Planned Early 2022 — Progress to clinical data collection</p>	<p><b>Opioid Use Disorders</b> Opioid Withdrawal Detection</p> <p>Planned Early 2022 — Progress to clinical data collection </p>		
<p><b>Anxiety &amp; Affective Disorders</b> Decision Support Platform</p> <p>In development — Concept development</p>		<p><b>Acute and Chronic Pain</b> Pain Measurement System</p> <p>Ongoing — Data collection for model development</p>	<p><b>Acute and Chronic Pain</b> Pain Reporting System</p> <p>Ongoing — In study Use </p>		
			<p><b>Parkinson's Disease</b> Tracking Platform</p> <p>Ongoing — Mobile Observational study with undisclosed pharma partner</p>		

■ PSYCHIATRY      ■ PAIN  
■ ADDICTION      ■ NEUROLOGY

# Corporate Information

# NASDAQ: MNMD // NEO: MMED // DE: MMQ

First Publicly Listed Psychedelic Biotech Company

## Share Ownership as of July 31, 2021

Executive Team/Directors/Insiders	65,468,007	13.8%
Non-insider shares	351,330,630	74.2%
Equity Incentive Plan (Issued)	33,082,892	7.0%
Outstanding Warrants	23,387,631	4.9%
Total (Fully diluted)	473,269,160	100%

# \$204 million

Raised since inception including warrants

# \$146 million

Cash position as of September 30, 2021



Market Cap: USD \$653 million Dec 31, 2021 (\$1.38 per share)

Market Cap: C\$823 million Dec 31, 2021 (C\$1.74 per share)



# Leadership: A Combination of Drug Developers & Technologists

## Robert Barrow

*Chief Executive Officer*



Rob is an accomplished pharmaceutical executive and clinical pharmacologist with over a decade of experience leading drug development programs in a variety of disease areas. Mr. Barrow previously served as Director of Drug Development & Discovery at Usona Institute, where he oversaw preclinical, clinical and regulatory development efforts for all of Usona's development programs. Prior to joining Usona, he served as Chief Operating Officer of Olatec Therapeutics where he oversaw the execution of numerous early- and late-stage clinical trials in the fields of analgesics, rheumatology, immunology and cardiovascular disease. Rob holds a Master's degree in Pharmacology from The Ohio State University and a Bachelor of Science degree from Wake Forest University, where he graduated summa cum laude.

## Miri Halperin Wernli, PhD

*Executive President & Board Director*



Miri co-founded Creso Pharma, a cannabis company, and listed the company on the Australian Stock exchange (ASX) in October 2016. Prior to founding Creso Pharma Dr. Halperin Wernli worked in clinical psychiatry in Swiss academic hospital settings and then held various global senior leadership positions in the pharma and biotech industries in Switzerland and in the US (Merck, Sharp and Dohme, Roche and Actelion pharmaceuticals) covering Product Development, R&D, and Strategic Marketing. Her extensive pharmaceutical industry and biomed research and development experience covers the full spectrum of areas and activities from Preclinical to Clinical Development and Strategy, to Drug Registration and Launch, across several Therapeutic Areas.

## Cynthia Hu, JD

*Chief Legal Officer & Corporate Secretary*



Cynthia joined in December 2021 as Chief Legal Officer & Corporate Secretary. Previously, from 2009-2021, she served as COO, General Counsel & Secretary at CASI Pharmaceuticals, Inc. and, from 2006 to 2009, as VP, General Counsel, of its predecessor, EntreMed, Inc. Prior to that, she served as senior associate for the corporate and finance practice group at Powell Goldstein LLP in Washington, DC, where she advised clients on all corporate and financing matters, including complex public and private financings, mergers and acquisitions, SEC and regulatory compliance, and corporate governance and compliance. Before that, Ms. Hu was counsel for a NYSE-listed financial institution and prior to that was in private law practice at Klehr, Harrison, Harvey & Branzburg, LLP and Littman & Krooks, LLP focusing on corporate transactions and compliance with corporate and securities laws.

## Daniel Karlin, MD, MA

*Chief Medical Officer*



Dan previously co-founded HealthMode in 2018 and served as CEO until its acquisition by MindMed. Before that, he built and led Clinical, Informatics, and Regulatory Strategy for Pfizer's Digital Medicine and Innovation Research Lab. He also served as Global Clinical Lead for psychiatry clinical compounds at Pfizer. Previously, he was the founder and Chief Medical Officer at Column Health, a leading technology-enabled psychiatry and addiction practice. He is a strategic advisor to multiple big pharma, and digital therapeutic companies. Dan is board Certified in Psychiatry, Addiction Medicine, and Clinical Informatics. He is an Asst. Prof. of Psychiatry at Tufts University School of Medicine. He graduated with degrees in Neuroscience and Behavior (BA), and Clinical Informatics (MA), Columbia University; Medicine (MD), University of Colorado School of Medicine.

## Dave Guebert

*Chief Financial Officer*



Dave Guebert is a CPA, qualified in both Alberta and Pennsylvania, and a Member of the Institute of Corporate Directors. He started his career in 1979 at Deloitte where he qualified for his CPA designations. He went on to serve as the Controller for the XV Olympic Winter Games from 1986 to 1988. Since then has taken on increasing senior roles, acting as Chief Financial Officer for a number of public and private companies, primarily in the technology industry. He currently sits as a board member and Audit Committee Chair for Legend Power Systems (TSXV: LPS), RMMI Inc. (CSE: RMMI) and Qusitive Technology Solutions, Inc. (TSXV: QUIS). From 2010 to 2017, he was board member and Audit Committee Chair of Merus Labs International Inc. (TSX: MSL; NSDQ: MSLI), a specialty pharmaceutical company.

# Board of Directors

## Carol Vallone

*Chair of the Board of Directors*



Ms. Vallone is a well-known business leader, former CEO, and corporate board director, with a strong track record in launching, scaling and selling global companies. Currently, she serves as Chair of the Board of Trustees at McLean Hospital, the #1 ranked freestanding psychiatric hospital and largest psychiatric affiliate of Harvard Medical School; serves on the board of trustees at MGH Institute of Health Professions; and serves on the finance committee at Mass General Brigham.

## Robert Barrow

*Chief Executive Officer and Director*



Mr. Barrow is an accomplished pharmaceutical executive and clinical pharmacologist with over a decade of experience leading drug development programs in a variety of disease areas. Mr. Barrow previously served as Director of Drug Development & Discovery at Usona Institute, where he oversaw preclinical, clinical and regulatory development efforts for all of Usona's development programs. Prior to joining Usona, Mr. Barrow served as Chief Operating Officer of Olatec Therapeutics where he oversaw the execution of numerous early- and late-stage clinical trials.

## Miri Halperin Wernli, PhD

*Executive President and Director*



Dr. Halperin Wernli previously worked in clinical psychiatry in Swiss academic hospital settings and then held various global senior leadership positions in the pharma and biotech industries in Switzerland and in the US (Merck, Sharp and Dohme, Roche and Actelion pharmaceuticals) covering Product Development, R&D, and Strategic Marketing.

## Sarah Vinson, MD

*Director*



Dr. Vinson is a Triple Board-Certified physician who specializes in adult, child & adolescent, and forensic psychiatry. She is the founder of Lorio Forensics. Dr. Vinson is an Associate Clinical Professor of Psychiatry and Pediatrics at Morehouse School of Medicine, where she is the Program Director of the Child & Adolescent Psychiatry Fellowship, and Adjunct Faculty at Emory University School of Medicine.

## Andreas Krebs

*Director*



Mr. Krebs heads the family-owned investment company Longfield Invest (Langenfeld/Germany), which focuses on growth companies in various industries as well as in the new economy. He was formerly Executive Board Member of Wyeth Corporation in the United States. Andreas Krebs was Chairman of the Supervisory Board and Shareholder Council of Merz Pharma, Frankfurt am Main, Germany from 2010 to 2019, is currently a member of the Supervisory Board of the European eye clinic group Veonet (Nordic Capital Group) and holds other board positions across various sectors.

## Brigid Makes

*Director, Chair of Audit Committee*



Brigid Makes served as Senior Vice President and Chief Financial Officer of Miramar Labs. Former CFO for Nektar Therapeutics (formerly Inhale Therapeutics) B.A. in Finance and International Business from McGill University and an M.B.A. from Bentley University. Brigid chairs the board's Audit Committee.

# Public Perception of Psychedelics Has Changed

## THE WALL STREET JOURNAL.

*"Psychedelics-Drug Startup Raises \$24 Million Ahead of IPO." February 27, 2020*

## Bloomberg

*"Its market capitalization of over C\$1 billion puts the company ahead of at least eight companies in Canada's benchmark S&P/TSX Composite Index, according to data compiled by Bloomberg." December 9, 2020*

## BUSINESS INSIDER

*"A startup that wants to use psychedelics to treat addiction just raised \$6.2 million from the host of Shark Tank and the architect behind the world's biggest cannabis grower" September 30, 2019*

## FASTCOMPANY

*"This could save lives, cure depression, help alcoholism, get people off opioids—why wouldn't I want to be invested?" -Kevin O' Leary  
December 9, 2019*

## THE NEW YORKER

*"New York is getting its first psychedelic-medicine center, with the help of a startup called MindMed, which develops hallucinogens to treat mental illness and addiction, and is funding an institute at N.Y.U. Langone Medical Center." October 12, 2020*

## FORTUNE

*"Psychedelic drugs may transform mental health care. And big business is ready to profit from the revolution." February 17, 2020*

## Forbes

*"Psychedelic Drug Company MindMed Applies For NASDAQ Up-Listing" September 25, 2020*

## TOWN&COUNTRY

*"The evidence for psychedelics as medicine is far greater than that for CBD, which companies are selling to relieve ills from Parkinson's to Crohn's." April 13, 2020*



36 STARTUPS  
that could change  
the world



**"MindMed named one of 36 startups that could change the world"** December 17, 2019



# Investment Highlights

Robust, long-term strategy with near-term value drivers

## MindMed Differentiator

Advancing novel drug class to transform mental health treatment

Leveraging therapeutic potential of LSD with first-in-class strategy

Building diverse, robust, and long-term development pipeline

Multiple near-term value-driving catalysts

Accelerating value through collaborations

## Investment Highlights

- Leveraging rigorous drug development principles and enabling digital therapeutics
  - Approach supported by long history of well-tolerated use in clinical studies
  - Tech enables market access and scale
- Diversified strategy across development franchise with multiple ongoing and planned clinical studies
  - Opportunity for accelerated development
- Diverse pipeline of NCEs and optimized molecules derived from classic psychedelics
  - Initial focus on psychiatry, addiction and neurology with opportunity to explore follow-on indications
  - 8 ongoing/planned Phase 2 studies & 4 ongoing/planned Phase 1 studies
- (Early 2022) Initiate Phase 2b trial of LSD for Generalized Anxiety Disorder (GAD)
  - (Early 2022) Release Top-line Results from Phase 1 trial of 18-MC for opioid withdrawal
  - (Early 2022) Initiate Phase 2a trial of 18-MC for opioid withdrawal
- Collaborations with leading research and academic institutions further validate approach
  - Collaborations and data acquisitions enable rapid path to development with significantly less risk

SCHE: attention deficit hyperactivity disorder; PTSD: post-traumatic stress disorder



# MindMed

# Sources

1. Mental Health By the Numbers | NAMI: National Alliance on Mental Illness. (2019). NAMI. <https://www.nami.org/mhstats#:~:text=20.6%25%20of%20U.S.%20adults%20experienced,represents%201%20in%2020%20adult>
2. Bandelow, Borwin, and Sophie Michaelis. "Epidemiology of anxiety disorders in the 21st century." *Dialogues in clinical neuroscience* vol. 17,3 (2015): 327-35.
3. Weiss, R. D., Potter, J. S., Fiellin, D. A., Byrne, M., Connery, H. S., Dickinson, W., Gardin, J., Griffin, M. L., Goirevitch, M. N., Haller, D. L., Hasson, A. L., Huang, Z., Jacobs, P., Kosinski, A. S., Lindblad, R., McCance-Katz, E. F., Provost, S. E., Selzer, J., Somoza, E. C., Sonne, S. C., ... Ling, W. (2011). Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. *Archives of general psychiatry*, 68(12), 1238–1246. <https://doi.org/10.1001/archgenpsychiatry.2011.121>
4. Kelly, K. M., & Mezuk, B. (2017). Predictors of remission from generalized anxiety disorder and major depressive disorder. *Journal of affective disorders*, 208, 467–474. <https://doi.org/10.1016/j.jad.2016.10.042>
5. Dahlhamer, J., Lucas, J., Zelaya, C., Nahin, R., Mackey, S., DeBar, L., Kerns, R., Von Korff, M., Porter, L., & Helmick, C. (2018). Prevalence of Chronic Pain and High-Impact Chronic Pain Among Adults - United States, 2016. *MMWR. Morbidity and mortality weekly report*, 67(36), 1001–1006. <https://doi.org/10.15585/mmwr.mm6736a2>
6. Hasin DS, Sarvet AL, Meyers JL, et al. Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States. *JAMA Psychiatry*. 2018;75(4):336–346. doi:10.1001/jamapsychiatry.2017.4602
7. 2019 National Survey on Drug Use and Health, 2020
8. Dahlhamer J, Lucas J, Zelaya, C, et al. Prevalence of Chronic Pain and High-Impact Chronic Pain Among Adults — United States, 2016. *MMWR Morb Mortal Wkly Rep* 2018;67:1001–1006. DOI: [http://dx.doi.org/10.15585/mmwr.mm6736a2external icon](http://dx.doi.org/10.15585/mmwr.mm6736a2external%20icon).
9. Wei DY, Yuan Ong JJ, Goadsby PJ. Cluster Headache: Epidemiology, Pathophysiology, Clinical Features, and Diagnosis. *Ann Indian Acad Neurol*. 2018;21(Suppl 1):S3-S8. doi:10.4103/aian.AIAN\_349\_17
10. Carhart-Harris RL, Leech R, Hellyer PJ, et al. The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs. *Front Hum Neurosci*. 2014;8:20. Published 2014 Feb 3. doi:10.3389/fnhum.2014.00020
11. Holze, F., Vizeli, P., Ley, L. et al. Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects. *Neuropsychopharmacol*. 46, 537–544 (2021). <https://doi.org/10.1038/s41386-020-00883-6>
12. Carhart-Harris RL, Muthukumaraswamy S, Roseman L, et al. Neural correlates of the LSD experience revealed by multimodal neuroimaging. *Proc Natl Acad Sci U S A*. 2016;113(17):4853–4858. doi:10.1073/pnas.1518377113
13. Dureja GP, Iyer RN, Das G, Ahdal J, Narang P. Evidence and consensus recommendations for the pharmacological management of pain in India. *J Pain Res*. 2017;10:709–736. Published 2017 Mar 29. doi:10.2147/JPR.S128655
14. Ramaekers, J. G., Hutten, N., Mason, N. L., Dolder, P., Theunissen, E. L., Holze, F., Liechti, M. E., Feilding, A., & Kuypers, K. P. (2021). A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers. *Journal of psychopharmacology (Oxford, England)*, 35(4), 398–405.13
15. M.I. (2020, May 6). The U.S. Mental Health Market: \$225.1 Billion In Spending In 2019: An OPEN MINDS Market Intelligence Report. OPEN MINDS. <https://openminds.com/intelligence-report/the-u-s-mental-health-market-225-1-billion-in-spending-in-2019-an-open-minds-market-intelligence-report/>
16. Danforth, A. L., Grob, C. S., Struble, C., Feduccia, A. A., Walker, N., Jerome, L., Yazar-Klosinski, B., & Emerson, A. (2018). Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study. *Psychopharmacology*, 235(11), 3137–3148. <https://doi.org/10.1007/s00213-018-5010-9>
17. Autism Statistics and Facts. (2017). Autism Speaks. <https://www.autismspeaks.org/autism-statistics-asd>
18. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. *Archives of General Psychiatry*. 2005;62:593–602.

